| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oleocanthal is essentially found ONLY in: Fresh, unrefined extra-virgin olive oil (EVOO) It is part of the pungent, throat-stinging phenolic fraction that disappears in refined oils. Oleuropein (OLEU) — a secoiridoid polyphenol from olive leaf and olive fruit/extra-virgin olive oil; major in-vivo related phenolic is hydroxytyrosol (via hydrolysis/metabolism). Sources: olive leaf extract (standardized to oleuropein), EVOO phenolics. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Human data show absorption/metabolism after oral olive leaf extract; circulating forms are largely metabolites (and hydroxytyrosol-related), with limited free parent compound exposure. :contentReference[oaicite:0]{index=0} In-vitro vs oral exposure: Many direct “anticancer” cytotoxic effects occur at micromolar concentrations that may exceed typical systemic exposure from supplements/foods (high concentration only for direct tumor cytotoxicity in many models). :contentReference[oaicite:1]{index=1} Clinical evidence status: Nutraceutical/food bioactive with human data mainly for cardiometabolic/inflammation endpoints; oncology evidence largely preclinical/adjunct-hypothesis (no oncology approval). Also available as a supplement usually labeled as Olive Leaf Extract. (20-50% concentrations)- commonly used in CSC (Cancer Stem Cell) research. Main CSC mechanisms: -Inhibits Wnt/β-catenin — a core CSC survival pathway -↓ALDH (Reduces ALDH-high CSC subpopulations) -downregulates stemness geens: SOX2/OCT4/Nanog → reduced sphere formation/self-renewal. Oleuropein — Cancer vs Normal Cell Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr Oleuropein — AD relevance: Oleuropein/olive leaf phenolics show neuroprotection in models via oxidative- and heat-shock/proteostasis stress responses, with reported reduction of Aβ and tau proteotoxicity in preclinical systems; human AD disease-modifying evidence is not established. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Human absorption/metabolism supports systemic exposure mainly as metabolites; brain relevance likely chronic/adaptive. :contentReference[oaicite:9]{index=9} Clinical evidence status: Predominantly preclinical for AD mechanisms; limited AD-specific clinical endpoint evidence. Oleuropein — AD / Neurodegeneration Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 4630- | OLE, | Targeting resistant breast cancer stem cells in a three-dimensional culture model with oleuropein encapsulated in methacrylated alginate microparticles |
| - | in-vitro, | BC, | NA |
| 4643- | OLE, | HT, | Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:375 Target#:42 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid